Hepatitis B vaccines market forecast to show moderate growth until 2018
The global hepatitis B vaccines market is estimated to be worth $997.0 million in 2010, and is forecast it to grow at a compound annual growth rate (CAGR) of 4.1% for the next eight years, to reach $1.38 billion by 2018 by industry analysis specialist GlobalData.
During the period 2005–2010, the market grew at a CAGR of 6.7%, from $720.5 million to $997 million. The growth is primarily attributed to the increase in the vaccination rate and coverage among different age groups, as a result of government programs and increased public awareness. The market would also be driven by birth population growth and the need for therapeutic vaccines in cases of cirrhosis, liver disease and primary liver cancer (hepatocellular carcinoma or HCC).
Highly competitive sector capable of catering to most market needs
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
| Headless Content Management with Blaze